Biotech News Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech News

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	9/5/2008 3:38:06 PM
	of 7143

Check out the results DNA achieved in breast cancer patients refractory to Herceptin and in some cases Tykerb with T-DM1, here's a link: www1.investorvillage.com If this trial concludes the way it's started, the data would be worthy of registration except for one problem, they weren't using Pivotal Quality Material. DNA is starting two new Phase II Trials both announced to be potentially registrational, and a decisions yet to be made on a Phase III. In my view the two Phase II's could lead to approval faster, so the need for a Phase III is somewhat questionable, but as an IMGN investor it would certainly be nice as IMGN would receive a substantial Milestone Payment. Otherwise it's uncertain when IMGN may collect a payment, though they're owed something in the $30+ million range by approval, then royalties start kicking in and hopefully grow to $100 million or more a year over a few years time. This would require the drug to exceed minimum blockbuster status, but if all trials are successful it should be the replacement for Herceptin in almost all cases, that should make it a blockbuster many times over in a few years after approval. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next